Methotrexate Exposure and Psoriasis Management in Early Pregnancy
A 31-year-old woman with moderate-to-severe chronic plaque psoriasis and psoriatic arthritis has been taking methotrexate 15 mg weekly with folic acid 1 mg daily for 3 years. She reports 2 weeks of nausea and a missed menstrual period; a home pregnancy test is positive. She is unsure of the date of conception. Her psoriasis covers 18% body surface area with thick plaques on the elbows and knees, and she has morning stiffness in the hands. She asks whether she must stop methotrexate immediately, what therapy is safe for the pregnancy, and whether she can breastfeed afterward. She is not currently on any biologic.
1. What immediate actions are required after a positive pregnancy test in a patient taking methotrexate, and what counseling should be given?
Read the worked answer
Immediate action: Stop methotrexate today. Do not give another dose. Methotrexate is a folate antagonist and is teratogenic; exposure in early pregnancy is associated with aminopterin syndrome, including cranial dysostosis, limb defects, and growth restriction. The risk depends on dose and timing, but any exposure warrants prompt cessation.
Counseling and next steps:
- Start high-dose folic acid 5 mg daily, which may reduce the risk of neural tube defects.
- Refer urgently to obstetrics for dating ultrasound, anomaly screening, and counseling. The patient may need maternal-fetal medicine input.
- Explain that the absolute risk after low-dose weekly methotrexate is not fully quantified, but stopping immediately is essential.
- Do not restart methotrexate during pregnancy or breastfeeding.
- Review all medications for other teratogens, including acitretin, mycophenolate, and retinoids.
- Document the discussion and arrange close follow-up.
Reassure the patient that many women with psoriasis have healthy pregnancies, but coordinated care is needed.
2. Recommend a treatment plan for her psoriasis and psoriatic arthritis during pregnancy, with rationale for each option.
Read the worked answer
Topical therapy: Emollients and low-to-medium potency topical corticosteroids are first-line for limited plaques. Avoid high-potency steroids over large areas because of systemic absorption.
Phototherapy: Narrowband UVB is safe in pregnancy and effective for widespread psoriasis. It is a good option for this patient if topical therapy is insufficient.
Systemic therapy for psoriasis and psoriatic arthritis:
- Certolizumab pegol is preferred among TNF inhibitors because it lacks an Fc fragment and has minimal placental transfer. It is effective for both skin and joints.
- Etanercept and adalimumab are alternatives with substantial pregnancy data; they are considered low risk.
- Cyclosporine can be used for severe psoriasis in pregnancy, with monitoring of blood pressure, renal function, and drug levels.
- Avoid methotrexate, acitretin, mycophenolate, and other teratogens.
Psoriatic arthritis: Certolizumab is a good choice because it treats both domains. Physical therapy and acetaminophen are adjuncts. Avoid NSAIDs in the third trimester.
Monitoring: Coordinate with rheumatology and obstetrics. Assess disease activity each trimester and adjust therapy.
3. Discuss lactation safety and monitoring through pregnancy and postpartum.
Read the worked answer
Lactation:
- Compatible: certolizumab, etanercept, adalimumab, cyclosporine, prednisone, and topical corticosteroids. TNF inhibitors are large molecules with poor oral bioavailability, so infant exposure is minimal.
- Avoid: methotrexate, acitretin, and mycophenolate. Methotrexate is contraindicated during breastfeeding because it accumulates in infant tissues and can cause toxicity.
- Phototherapy can continue during breastfeeding.
Monitoring through pregnancy:
- Track psoriasis body surface area and joint symptoms each trimester.
- Monitor fetal growth, especially if cyclosporine is used.
- Check blood pressure and renal function if on cyclosporine.
- Plan delivery with obstetrics, and inform anesthesia if the patient is on a biologic.
Postpartum:
- Watch for a postpartum flare and have a treatment plan in place.
- Continue certolizumab or another compatible biologic if needed.
- Screen for postpartum depression, which is more common in women with chronic inflammatory disease.
- Reassess contraception and avoid methotrexate until breastfeeding is complete. Provide reliable contraception if methotrexate is restarted.